Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017
|
|
- Shannon Reeves
- 6 years ago
- Views:
Transcription
1 Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017
2 Biopharmaceutical Classification System Approximately 80% of drugs in the pharmaceutical compounds pipeline exhibit low solubility and fall into the Biopharmaceutics Classification System (BCS) Class II or IV with the majority of these compounds being Class II (poor solubility, high permeability). 2008;7: CPHI DAVID K. LYON, PH.D. OCTOBER 25,
3 Important Properties to Define Problem Statement Dose / Dosage Format Solubility Lipophilic/ Hydrophobic / Ionic Structure/ MW Pharmacokinetics / Pharmacodynamics Pre-systemic metabolism CYP3A4 P-gp Efflux Bi-layer Permeability Polar Surface Area CPHI DAVID K. LYON, PH.D. OCTOBER 25,
4 Problem Statement Definition Guides Technology Choice Goal is to efficiently arrive at product development with certainty of approach SDD LIPIDIC NXSTAL Product Concept HME Technology/Formulation Molecule Problem Statement Prediction Product Development In vitro, in silico, & in vivo testing CPHI DAVID K. LYON, PH.D. OCTOBER 25,
5 Many Enabling Technologies Are Available Solid-State Alteration: Form, Particle Size Polymorphs New crystal compound Solid dispersions SDD, HME Cocrystals Lyophiles Salts Drug/polymer nanoparticles Nanocrystals (200 to 800 nm) Nanocrystals (<50 nm) Solvation, Complexation Cosolvents Surfactants Cyclodextrins Lipids: Oils SEDDS/SMEDDS Solid lipid pellets CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017 H.D. Williams et al. Strategies to Address Low Solubility in Discovery and Development, Pharmacol Rev, 65(2013) CPHI DAVID K. LYON, PH.D. OCTOBER 25,
6 Conceptual Guidance Map for Technology Selection Based on Molecular Properties and Dose H.D. Williams et al. Strategies to Address Low Solubility in Discovery and Development, Pharmacol. Rev., 65(2013), CPHI DAVID K. LYON, PH.D. OCTOBER 25,
7 Proposed Lipid/Amorphous Dispersion (ASD) Technology Guide Bioavailability Attribute Lipid ASD Comments Increase & Sustain Solubility X XX Reduce Efflux XX X Induce Fed State Promote Lymphatic Absorption Reduce Luminal Metabolism Decrease Hepatic Metabolism XX XX XX Reduce Food Effect X X X X X Primary ASD Performance Differentiator ASD Fasted Absorption Lipids Fed State Selected Other Attributes Lipid ASD Comments Tablet (Bias, capitalization) Patient Perception Commercial Precedence XX XX Dose per volume X XX IP Combine w/ Modified Release X X X XX 70% of oral DF are tablets ASDs Kinetic Lipids Thermodynamic Coatings, Osmotics, Matrix Critical Lipid Differentiators Critical ASD Differentiators CPHI DAVID K. LYON, PH.D. OCTOBER 25,
8 In Vitro Dissolution Testing is a Critical Tool for Assessing Oral Drug Product Bioperformance? source: M. Blewett CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017
9 Amorphous Enhancement & Polymer Sustainment Amorphous solubility defines solubility advantage for ASDs Polymer sustainment identifies excipient interactions & lead crystallization inhibitors CPHI DAVID K. LYON, PH.D. OCTOBER 25,
10 Membrane Test Compares ability of formulations to enhance free drug concentration at membrane surface Able to properly account for micelle, colloid, and particle contribution to boundary layer diffusion and dissolution rate Stewart et al. Mol. Pharmaceutics 2017, 14, CPHI DAVID K. LYON, PH.D. OCTOBER 25,
11 Digestion Test Digestion tests are used to identify those formulations at low risk of showing drug precipitation in the intestine Provides a performance-based means to select lead formulations Measure digestion by titration Dosing units Sample and measure drug fate by HPLC Overhead stirrer ph probe Oil A q Pelle t Reaction vessel CPHI DAVID K. LYON, PH.D. OCTOBER 25,
12 Gastric Stomach Duodenum Transfer Test Investigate interplay of gastric environment and precipitation with continual drug transfer UV Detection Example Precipitation of a Weak Base with and without Polymer CPHI DAVID K. LYON, PH.D. OCTOBER 25,
13 In Vitro Testing is Based on the Formulation Approach and Risk Assessment Example of Using a Risk-Based Approach to In Vitro Testing (Compound X SDD) Preliminary Assessment Problem Statements ASD Screening Refined Problem Statements LogP Tm, Tg, Tm/Tg pka Aq. Sol Amorphous. Solubility Organic solubility Dose Gastric ph effect? MAD calculation Gastric ph Dependent Dissolution Low Solvent Solubility Crystallization-Storage Chemical Degradation-Processing Chemical Degradation-Storage 3-5 small scale SDDs mfr d SEM, PXRD DSC vs.rh Purity/assay UV transfer disso, multiple gastric ph Gastric ph Dependent Dissolution Low Solvent Solubility Crystallization-Storage Chemical Degradation-Processing Chemical Degradation-Storage Precipitation Stomach (high ph) Precipitation Intestine Good formulation approach identified before investing lots of Time and Money here Detailed Assessment of Performance, Stability, and Manufacturability CPHI DAVID K. LYON, PH.D. OCTOBER 25,
14 14 Case Studies CPHI DAVID K. LYON, PH.D. October 25, 2017
15 Celecoxib Physicochemical Properties SDD NSAID Lipid Properties MW 381 LogP 4 T m 163 C T g 60 C T m /T g (K/K) 1.3 pk a (Acidic) 11 Aqueous Solubility (µg/ml) 0.01N HCl ph 2 ~10 PBS ph 6.5 ~10 FaSSIF ~50 PK Dose (mg) 400 Permeability, P app High Efflux No Pre-systemic metabolism No CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017
16 In Vitro and Clinical Performance of 50% Celecoxib: HPMCAS-L SDDs Formulation: Evaluated multiple formulation options varying polymer and process (HME) 50% HPMCAS-L selected as lead due to dissolution rate Species are colloidal, dissolved, and micellar drug Performance: Supersaturation sustains through 50 minutes in µdisso test (worst case) Supersaturation ratio is measured at approximately 10x vs crystalline. Colloidal drug present appears larger Clinical data shows rank order increase but not IVIVC In Vitro Dissolution Clinical PK Data CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017
17 Lipid Formulation Provides Limited BA Enhancement Lipid Formulation Celebrex CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017 N. Subramanian et al. Biol. Pharm. Bull. 27 (12) (2004) CPHI DAVID K. LYON, PH.D. OCTOBER 25,
18 Increased Bioavailability and Rapid Onset using Amorphous Nanoparticles 1:1 Celecoxib : Ethyl Cellulose NP in Casein HPMCAS based SDD Commercial Capsule Morgen, M.M., et al., Pharm. Res., 29:2(2012) CPHI DAVID K. LYON, PH.D. OCTOBER 25,
19 Technology Feasibility Program for Compound A SDD Lipid Physiochemical Properties MW ~500 LogP 5 T m T g ~150 C ~30 C T m /T g (K/K) ~1.4 pk a (Basic) ~5 Aqueous Solubility (µg/ml) 0.01N HCl ph 2 ~20 PBS ph 6.5 <1 FaSSIF ~20 FeSSIF ~150 PK Dose (mg) ~ 400 Bioavailability (fasted) 10% Food Effect Up to 10x CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017
20 Summary of SDD Performance in Feasibility Formulation: Evaluated 7 SDDs A% using 3 grades HPMCAS, PVPVA and HPMC 25-50A% HPMCAS-L selected as lead Aggressive loading compromised with dose & pill burden Performance: Supersaturation sustains through 30 minutes in GB-IB dissolution test Supersaturation ratio is measured at approximately 20x vs. crystalline Particle size and active loading affect dissolution rate CPHI DAVID K. LYON, PH.D. OCTOBER 25,
21 Follow-up Dissolution Testing Suggests Rapid Precipitation with Slow Crystal Growth UV method developed to independently track concentration of dissolved drug and nanocrystalline drug Independent light microscopy confirms rapid formation of small drug crystals CPHI DAVID K. LYON, PH.D. OCTOBER 25,
22 Summary Lipid Performance in Feasibility Digestion of lead formulations under simulated fasted state conditions: No evidence of precipitation before start of digestion Two lead formulations identified that effectively inhibit crystallization Supersaturation ratio is approximately 20x relative to crystalline in FaSSIF CPHI DAVID K. LYON, PH.D. October 25,
23 Technology Comparison of Compound A at 250 mg Dose (Canine, N=6) Key findings: LFHC and LMP technologies give the highest BA increase (~10 x relative to commercial product), reducing the food-effect to ~1.6x at the 250 mg dose High exposure in the fasted state when using LFHC or LMP suggests strong possibility of a significant dose reduction Variability was lowest for LMP technology Commercial Product Fasted SDD Fasted (2x 125mg tablets) T6-LFHC Fasted (3x 83.3mg capsules) Commercial Product Fed LMP Fasted (4x 62.5mg capsules) CPHI DAVID K. LYON, PH.D. October 25,
24 Summary Thoughts Formulation selection can be challenging for certain compounds in silico tools, in vitro tools, and historical experience can be used to focus on technologies and formulations with highest possibility of success Developing an in vivo predictive dissolution test requires understanding rate limiting step(s) to absorption Developing in vitro and in silico tools to directly compare critical performance attributes of different enabling technologies will enable more certainty in selection of the approach Building historical data set with multiple technologies will lead to improved technology selection based on: Product concept Physicochemical properties in vitro tools CPHI DAVID K. LYON, PH.D. October 25,
25 Three Sisters at Dawn Bend, Oregon USA
Approaches to the formulation of poorly soluble drugs
1 Approaches to the formulation of poorly soluble drugs R. Christian Moreton, Ph.D FinnBrit Consulting ExcipientFest 2013, April 30 May 01, 2013, Baltimore, MD 2 Disclaimer The views expressed in this
More informationA practical computational tool to predict formulation and process variables during the development of spray-dried amorphous solid dispersions.
A practical computational tool to predict formulation and process variables during the development of spray-dried amorphous solid dispersions. Íris Duarte, José Luís Santos, João F. Pinto, Márcio Temtem
More informationImproving Oral Bioavailability by Solid Dispersions: An OSPHENA (Ospemifene) Case Study
Improving Oral Bioavailability by Solid Dispersions: An OSPHENA (Ospemifene) Case Study Zhengming (Jimmy) Chen, Ph.D., Shionogi Inc. zhengming.chen@shionogi.com Shionogi Global Business Locations London
More informationRecent FDA Guidance For Industry; BCS Class 1 and 3 August 2015
Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015 Bryan Crist Scientific Affairs Manager, Agilent Technologies, Dissolution Systems Dissolution Exchange WebEx Bryan.crist@agilent.com August,
More informationAbstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2
Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has
More informationOutline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD
CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables
More informationDesign and Dosage Form. Dr. Deny Susanti
Design and Dosage Form Dr. Deny Susanti Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note:
More informationScience-Based Technology Selection And Formulation Development For Oral Bioavailability Enhancement
Science-Based Technology Selection And Formulation Development For Oral Bioavailability Enhancement Capsugel Dosage Form Solutions White Paper Authors: Hywel Williams, Michael Morgen, Eduardo Jule, Jan
More informationIn vitro in vivo correlations (IVIVC) can be summarized
dx.doi.org/10.14227/dt220215p44 Use of IVIVC to Optimize Generic Development J.-M. Cardot *, G. Garrait, and E. Beyssac e-mail: j-michel.cardot@udamail.fr Auvergne University, UFR Pharmacie, EA4678, Biopharmaceutical
More informationBiowaivers and Harmonization Guidelines for Class I and 3 Drugs: Biowaiver Case Studies
Biowaivers and Harmonization Guidelines for Class I and 3 Drugs: Biowaiver Case Studies Barbara M. Davit, Merck & Co., Inc. 3 rd FDA/PQRI Conference on Advancing Product Quality March 22, 2017 Disclaimer
More informationBCS Guidance and Biowaivers BCS Monographs
BCS Guidance and Biowaivers BCS Monographs Vinod P. Shah, Ph.D., Pharmaceutical Consultant PQRI Board Member 2 nd FDA/PQRI Conference on Advancing Product Quality Emerging Regulatory Initiatives Biopharmaceutics
More informationHow Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products
How Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products James E. Polli jpolli@rx.umaryland.edu September 17, 2014 Perspective The societal promotion of generic products
More informationThe role and future of dissolution testing in a QBD product development framework
The role and future of dissolution testing in a QBD product development framework Paul Dickinson, AstraZeneca, Alderley Park, Cheshire Senior Clinical Pharmacology Scientist paul.dickinson@astrazeneca.com
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationCHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE
CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE Paul Stott, PhD Head of US Product Development AstraZeneca ICH Quality Guidelines Workshop BioKorea 2007 Sept 13-14
More informationReflection paper on the dissolution specification for generic solid oral immediate release products with systemic action
10 August 2017 EMA/CHMP/CVMP/QWP/336031/2017 Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP) Reflection paper
More informationDissolution Methodologies from Biorelevant to Quality Control The Challenges and Gaps
Dissolution Methodologies from Biorelevant to Quality Control The Challenges and Gaps Xujin Lu 1, Jian-Hwa Han 2, Danna Mattocks 3 1 Analytical Science, DPST, Bristol-Myers Squibb Company 2 NCE-Analytical
More informationDissolution testing of solid oral dosage forms has
dx.doi.org/1.14227/dt22315p1 A Strategy for Quality Control Dissolution Method Development for Immediate-Release Solid Oral Dosage Forms Gerard M. Bredael 1,*, Steve Liang 2, and David Hahn 3 1 Pharmaceutical
More informationBalancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL
Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels
More informationKollidon SR: A polyvinyl acetate based excipient for DCsustained-release
Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release oral dosage forms by Dr. Bernhard Fussnegger BASF Aktiengesellschaft, Ludwigshafen Strategic Marketing Pharma Excipients Introduction
More informationHow do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?
Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental
More informationBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies Standard Approach Part I: Design and Conduct H. Rettig, Ph.D. LLC www.ivivc.com Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98
More informationAAPS Workshop on the Role of Dissolution in QbD and Drug Product Life Cycle: A Commentary
dx.doi.org/10.14227/dt170410p41 AAPS Workshop on the Role of Dissolution in QbD and Drug Product Life Cycle: A Commentary e-mail: susan.dsouza@sunovion.com Susan S. D Souza 1, * Ruben Lozano 2, Stephen
More informationQuality by Design for ANDAs: An Example for Immediate-Release Dosage Forms
Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms Introduction to the Example This is an example pharmaceutical development report illustrating how ANDA applicants can move toward
More informationGuideline on quality of oral modified release products
1 2 3 23 August 2012 EMA/492713/2012 Quality Working Party (QWP) 4 5 Draft Draft Agreed by QWP May 2012 Adoption by CHMP for release for consultation 19 July 2012 Start of public consultion 15 September
More information"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY
"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo
More informationBiowaiver Approaches for Generic Drug Products in the US: Case Studies
About OMICS Group OMICS Group is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information
More informationSolid Dispersions for Oral Administration: An Overview of the Methods for their Preparation
Send Orders for Reprints to reprints@benthamscience.ae REVIEW ARTICLE Current Pharmaceutical Design, 2016, 22, 1-17 1 Solid Dispersions for Oral Administration: An Overview of the Methods for their Preparation
More informationGuideline on quality of oral modified release products
20 March 2014 EMA/CHMP/QWP/428693/2013 Committee for Medicinal Products for Human Use (CHMP) Final Draft Agreed by QWP May 2012 Adoption by CHMP for release for consultation 19 July 2012 Start of public
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationPLGA Nanoparticles. Production and In Situ Drug Loading Using the NanoAssemblr Benchtop Instrument and the Impact of Solvent Removal Methods.
Create Transformative Medicines TM PLGA Nanoparticles Production and In Situ Drug Loading Using the NanoAssemblr Benchtop Instrument and the Impact of Solvent Removal Methods. S.M. Garg, A. Thomas, G.
More informationBest Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Specifications Breakout Session 2 Pete Yehl and Mike Coutant, moderators
More informationOctober 26-27, 2017 in Mumbai, India
ELECTROLAB, in collaboration with Simulations Plus, presents: The 2-Day GastroPlus Pharmaceutical Development Workshop October 26-27, 2017 in Mumbai, India Electrolab, in collabration with Simulations
More informationComputation of Solubility parameters using Molecular. dynamics simulation
Appendix I Appendix I Computation of Solubility parameters using Molecular dynamics simulation Computational Methods Molecular dynamics (MD) simulations were carried out using the Accelrys Materials Studio[1]
More informationMycophenolate Mofetil: Use of a Simple Dissolution Technique to Assess Generic Formulation Differences
dx.doi.org/10.14227/dt190112p52 Mycophenolate Mofetil: Use of a Simple Dissolution Technique to Assess Generic Formulation Differences e-mail: emmanuel.scheubel@roche.com Emmanuel Scheubel 1,2,*, Laurent
More informationDesign and Evaluation of Sustained Release Tablets containing Solid dispersion of Ziprasidone hydrochloride
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.6, No.3, pp 959-968, July-Aug 2014 Design and Evaluation of Sustained Release Tablets containing Solid dispersion of
More informationQuality by Design Specifications for Solid Oral Dosage Forms: Multivariate Product and Process Monitoring for Managing Drug Quality Attributes
Quality by Design Specifications for Solid Oral Dosage Forms: Multivariate Product and Process Monitoring for Managing Drug Quality Attributes by the Specification Design and Lifecycle Management Working
More informationControlled Release Drug Delivery from Hydrogels
Controlled Release Drug Delivery from Hydrogels Teacher s Guide Keith Neeves CSIP Graduate Fellow Cornell University 1 Overview The objective of this project is to introduce students to the concepts of
More informationFormulation and in vitro evaluation of bosentan osmatic controlled release tablets
IJPAR Vol.4 Issue 4 Oct- Dec -2015 Journal Home page: ISSN: 2320-2831 Research article Open Access Formulation and in vitro evaluation of bosentan osmatic controlled release tablets Mohammed Asif Hussain,
More informationQuantitation of amorphous content
13 Quantitation of amorphous content Amorphous fractions can significantly change the physicochemical properties of active pharmaceutical ingredients and drug products. Solvias offers a variety of analytical
More informationExperimental design on product development
Experimental design on product development Introduction What is the traditional developing method? What is experimental design? What do we need and what kind of possibilities do we have for designing?
More informationThe Emerging Technology Program: FDA s Perspective
The Emerging Technology Program: FDA s Perspective Mohan Sapru, M.S., Ph.D. Member Emerging Technology Team (ETT) CMC Lead Application Technical Lead Office of New Drug Products Office of Pharmaceutical
More informationMETHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow
METHOCEL Cellulose Ethers A product that can do it all TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow The possibilities are endless Pharmaceutical companies are continuously
More informationPK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis
More informationModeling and simulation of drug release through polymer hydrogels. Shantanu Maheshwari, Sivakumar Cherlo, Rama Subba Thavva and Venkataramana Runkana
Modeling and simulation of drug release through polymer hydrogels Shantanu Maheshwari, Sivakumar Cherlo, Rama Subba Thavva and Venkataramana Runkana 1 Drug delivery: Key challenges Oral delivery Currently,
More informationBiopharmaceutics Classification System: A Regulatory Approach
dx.doi.org/10.14227/dt180111p31 Biopharmaceutics Classification System: A Regulatory Approach B. Basanta Kumar Reddy 1, * and A. Karunakar 2 1 Regulatory Affair Dpt., Indchemie Health Specialities Pvt.
More informationBRITISH BIOMEDICAL BULLETIN
Journal Home Page www.bbbulletin.org BRITISH BIOMEDICAL BULLETIN Original Formulation and In vitro Evaluation of Metoprolol Succinate Extended Release Pellets Ch.Kalyani 1*, K. Veer Reddy 1, E.Anka Rao
More informationSelf-assembling Nanomedicine for Oncology
Self-assembling Nanomedicine for Oncology L. Harivardhan Reddy Pharmaceutical Sciences Department Sanofi-Aventis Research & Development EU-US FOE Symposium 2010, Cambridge 1-3 Sept 2010 List of contents
More informationRecent Advances in Oral Granules and Bi-Layer Tablet Technologies, Solubility Enhancement Solutions, and Oral Disintegrating Tablet Applications
Recent Advances in Oral Granules and Bi-Layer Tablet Technologies, Solubility Enhancement Solutions, and Oral Disintegrating Tablet Applications Michael J. Valazza, R.Ph. Vice President Global Modified
More informationUSP Hypromellose Phthalate
USP Hypromellose Phthalate HPMCP: CONTENTS PAGE 2 Preface Designation and structural formula of HPMCP Designation, Admissions to compendia, Chemical name Trade name Structural formula Physico-chemical
More informationRajesh Kaza. et al /J. Pharm. Sci. & Res. Vol.1(4), 2009,
Design and Evaluation of Sustained release Floating tablets for the treatment of Gastric Ulcers Rajesh Kaza* 1, E. Usharani 2, R.Nagaraju 2, R.Haribabu 3 and P.V.Siva Reddy 4 1* Sree Vidyanikethan College
More informationPharma Silica Insights
high low permeability Pharma Silica Insights A newsletter for silica excipients for pharmaceutical formulations Issue 1 2012 What about silica? AEROSIL colloidal silicon dioxide is a well known excipient
More informationSolubility enhancement of poorly soluble API using cellulose derivatives. 28th April 2014 Shilpa Mistry
Solubility enhancement of poorly soluble API using cellulose derivatives 28th April 2014 Shilpa Mistry Class up to improve drug solubility BCS :Biopharmaceutics Classification system *1 More than 60% of
More informationGuideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation
1 2 3 21 July 2016 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling
More informationIdentification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study
Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study Ajit S. Narang, Ph.D. Bristol-Myers Squibb, Co. 2 nd FDA/PQRI Conference on Advancing Product Quality Bethesda,
More informationUtilizing In Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation
Utilizing In Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation CHRISTIAN WAGNER, 1 KIRSTIN THELEN, 2 STEFAN WILLMANN, 2 ARZU SELEN,
More informationNISSO HPC for Pharmaceutical Applications
NISSO HPC for Pharmaceutical Applications Contents Introduction Features of NISSO HPC Major Application of NISSO HPC NISSO HPC Grades and Availability How to use based on Application and Features of NISSO
More informationPharmaceutical Sciences/Medicinal Chemistry, M.S.
Pharmaceutical Sciences/Medicinal Chemistry, M.S. 1 Pharmaceutical Sciences/Medicinal Chemistry, M.S. SCHOOL OF PHARMACY (http://www.temple.edu/pharmacy) About the Program The School of Pharmacy offers
More informationTEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES
VICH GL39 (QUALITY) November 2005 For implementation at Step 7 TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES Recommended for
More informationControlling drug delivery
Sample chapter copyright Pharmaceutical Press www.pharmpress.com chapter 1 Controlling drug delivery Overview In this chapter we will: differentiate drug delivery systems according to their physical state
More informationDeveloping and Validating Dissolution Procedures for Improved Product Quality
W H I T E P A P E R Developing and Validating Dissolution Procedures for Improved Product Quality By Michael Swartz, Ph. D., Director of Research and Development, and Mark Emanuele, Chemist Abstract In
More informationPreparation of Cefpodoxime Proxetil - Polymeric Microspheres by the Emulsion Solvent Diffusion Method for taste masking
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol. 3, No.1, pp 411-419, Jan-Mar 2011 Preparation of Cefpodoxime Proxetil - Polymeric Microspheres by the Emulsion Solvent
More informationCase Study: Merck & Co., Inc.
Case Study: Merck & Co., Inc. Use of In Vivo Pharmacokinetic Data to Develop a CRS for In Vitro Dissolution Testing Barbara M. Davit Merck & Co., Inc. ( Merck ) UMD/FDA CERSI Workshop May 17, 2017 Implementing
More informationMethod Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology
Technical Overview Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology Introduction Online fiber-optic and multicell UV-dissolution systems have become increasingly
More informationInvestigating Differences in Solubility Between Crystalline and Amorphous Forms of Pharmaceuticals
Investigating Differences in Solubility Between Crystalline and Amorphous Forms of Pharmaceuticals Rhea Brent Pharmaceutical Analytical Research and Development AstraZeneca Alderley Park Aim To determine
More informationApplications of USP Apparatus 3: Reciprocating Cylinder
Applications of USP Apparatus 3: Reciprocating Cylinder Ken Boda Bryan Crist Agilent Technologies Current Trends in Pharmaceutical Dissolution Testing Workshop Pittcon 2015 Tuesday, March 10 Development
More informationmacrofilaricide Robert Don Discovery and Preclinical Director
Development of Flubendazole as a macrofilaricide Robert Don Discovery and Preclinical Director DNDi s Main Objectives Most Neg glected Use and strengthen existing capacity in disease- endemic countries
More informationBASIC PHARMACOKINETICS AND PHARMACODYNAMICS
BASIC PHARMACOKINETICS AND PHARMACODYNAMICS An Integrated Textbook and Computer Simulations SARA ROSENBAUM ~ WILEY A lohn WILEY & SONS, INC., PUBLICATION CONTENTS Preface 1 Introduction to Pharmacokinetics
More informationSession 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationDesign and Evaluation of a new Capsule-type Dosage form for Colon-Targeted Delivery of Etoricoxib
International Journal of Pharma Sciences Vol. 3, No. 1 (2013): 147-151 Research Article Open Access ISSN: 2249-8214 Design and Evaluation of a new Capsule-type Dosage form for Colon-Targeted Delivery of
More informationDesign and development of floating In-Situ gel of pantoprazole
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (8):239-249 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationFigure 1. Standard spray congealing setup.
Conrad Winters Spray congealing: applications in the Pharmaceutical Industry PAULA CORDEIRO, MÁRCIO TEMTEM, CONRAD WINTERS* *Corresponding author Hovione, R&D, Drug Product Development Group, Sete Casas,
More informationMitigating Patient Risks Using Dissolution Testing in Manufacturing Extended Release Products
Mitigating Patient Risks Using Dissolution Testing in Manufacturing Extended Release Products Yihong Qiu, Ph.D. October 5-7, 2015 Dissolution Testing and Specification for ER Products in Emerging Regulatory
More informationThe Challenges of Designing Cyclic Prodrugs of Opioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier
The Challenges of Designing Cyclic Prodrugs of pioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier Ronald T. Borchardt Department of Pharmaceutical Chemistry The University of
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Ravneet Kaur,, 2012: Volume1 (2):94-101 ISSN: 2277-8713 RESEARCH ARTICLE INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE A Path for Horizing Your Innovative Work EXPLORATION OF DIFFERENT
More informationEnhancement of dissolution rate of poorly-soluble active ingredients by Supercritical Fluid processes. Part II: Preparation of composite particles
Enhancement of dissolution rate of poorly-soluble active ingredients by Supercritical Fluid processes. Part II: Preparation of composite particles Formulation processes: Michel PERRUT, Jennifer JUNG, Fabrice
More informationIMPROVEMENT OF CARVEDILOL DISSOLUTION RATE THROUGH FORMATION OF INCLUSION COMPLEX WITH Β-CYCLODEXTRIN
Innovare Academic Sciences International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 6, Issue 4, 2014 Original Article IMPROVEMENT OF CARVEDILOL DISSOLUTION RATE THROUGH FORMATION
More informationCARBOXYMETHYL CELLULOSE NANOCOMPOSITES
CARBOXYMETHYL CELLULOSE NANOCOMPOSITES YongJae Choi Department of Chemical Engineering and John Simonsen Department of Wood Science & Engineering Oregon State University Outline I. Introduction II. Materials
More informationMultisource (generic) pharmaceutical products: guidelines on registration requirements to establish
Annex 7 Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability 1 1. Introduction 134 2. Glossary 135 3. Documentation of equivalence for
More informationdrug discovery: Where are we now? How did we RSC February 2013
The role of pharmacokinetics in drug discovery: Where are we now? How did we get th here??where are we going? Peter Webborn RSC February 2013 Why conduct PK studies in animals? The primary purpose of pre-clinical
More informationRE: CPMT Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis
Suzanne Hill, M.D. Essential Medicines and Pharmaceutical Policies World Health Organization Geneva, Switzerland RE: CPMT-08-011 Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis
More informationDesign and Development of Polyethylene Oxide Based Matrix Tablets for Verapamil Hydrochloride
Research Paper Design and Development of Polyethylene Oxide Based Matrix Tablets for Verapamil Hydrochloride S. VIDYADHARA, R. L. C. SASIDHAR* AND R. NAGARAJU 1 Department of Pharmaceutics, Chebrolu Hanumaiah
More informationPharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148
Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP
More informationINTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES
INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES Effect of various polymers on swelling and in vitro release of ramipril in effervescent system Sudheer Nadendla*,Snehalatha, T.S.Nagaraja and Bharathi
More informationResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Improved Physicochemical Characteristics of Amorphous Drug Solid Dispersions Department of Pharmaceutics, SVCP, Hyderabad, India. A
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationPharma & Food Solutions. ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications
Pharma & Food Solutions ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications ETHOCEL Premium Polymers are essentially tasteless, colorless, odorless, noncaloric
More informationTransdermal Drug Delivery System Regulatory Requirements (USA)
Transdermal Drug Delivery System Regulatory Requirements (USA) Vinod P. Shah, Ph. D., FIP Scientific Secretary Conference on To and Thru the Skin IPA AAPS FIP - APSTJ Mumbai, India, February 20-21, 2009
More informationBEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development
- ASPECTS OF COMPOUNDING PRODUCT DESIGN Reinout C.A. Schellekens, PharmD, RHPh, QP Head Clinical Drug Production and Development Department of Hospital and Clinical Pharmacy University Medical Center Groningen,
More informationThe objective of this study was to investigate solid dispersions (SDs) of poorly water soluble drug carbamazepine (CBZ),
ORIGINAL ARTICLE Solubility and dissolution enhancement of HPMC based solid dispersions of carbamazepine by hot melt extrusion technique Sharadchandra Dagadu Javeer, Purnima Dhanraj Amin Department of
More informationPharmaceutical Sciences/Medicinal Chemistry, Ph.D.
Pharmaceutical Sciences/Medicinal Chemistry, Ph.D. 1 Pharmaceutical Sciences/Medicinal Chemistry, Ph.D. SCHOOL OF PHARMACY (http://www.temple.edu/pharmacy) About the Program The School of Pharmacy offers
More informationDevelopment of Biomaterials & Devices from Renewable Resources
Development of Biomaterials & Devices from Renewable Resources Prof. Dr. Marie-Pierre Laborie Dr. ir. Pieter Samyn Institute for Forest Utilization and Works Science Werthmannstrasse 6 79085 Freiburg im
More informationGeology 627, Hydrogeology Review questions for final exam h t 1/ 2
Geology 67, Hydrogeology Review questions for final exam 004 Multiple choice and fill in the blank. There may be more than one correct choice for each question. 1. Which hydrogeologic quantities are represented
More informationFunctionalized Calcium Carbonate (FCC) FCC: Newly developed structured minerals as multifunctional excipients
Functionalized Calcium Carbonate (FCC) FCC: Newly developed structured minerals as multifunctional excipients ExcipientFest Americas, San Juan, PR April 29 th 2015 Dr. Carolina Diaz Quijano_ carolina.diazquijano@omya.com
More informationFor International Journal of Pharmaceutics. April 18, A Science Based Approach to Topical Drug Classification System (TCS)
For International Journal of Pharmaceutics. April 18, 2015 A Science Based Approach to Topical Drug Classification System (TCS) 5 Vinod P. Shah 1,5, Avraham Yacobi 2, Flavian Ștefan Rădulescu 3, Dalia
More informationApplication Note. Introduction. Analysis of crystal polymorphism by Raman Spectroscopy for Medicine Development
Application Note Analysis of crystal polymorphism by Raman Spectroscopy for Medicine Introduction Crystal polymorphism is a phenomenon where Raman applications in the pharmaceutical Industry compounds
More informationGDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS
GDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS 4 th Annual Symposium on Development of Generics & 505(b)(2) Achieving Access to Complex Drug Products: Integrating Scientific and
More informationClinically Relevant Dissolution Specifications: FDA Perspective and Initiatives
Clinically Relevant Dissolution Specifications: FDA Perspective and Initiatives 2015 GPhA CMC Workshop June 10, 2015 Paul Seo, Ph.D. Division Director (Acting) OPQ/ONDP/Division of Biopharmaceutics 1 Outline
More informationDIRECTLY COMPRESSIBLE MEDICATED CHEWING GUM (MCG) FOR STAYING ALERT
DIRECTLY COMPRESSIBLE MEDICATED CHEWING GUM (MCG) FOR STAYING ALERT July 2012 Introduction Medicated chewing gums are defined by the European Pharmacopoeia 1 and the guidelines for pharmaceutical dosage
More information